Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

SUGAMMADEX CIPLA 100 MG/ML SOLUCION INYECTABLE EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/SUGAMMADEX CIPLA 100 MG/ML SOLUCION INYECTABLE EFG

Approved

STANDARD

SUGAMMADEX CIPLA 100 MG/ML SOLUCION INYECTABLE EFG

Cipla Europe🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Nov 25, 2022
Approval ID: cea82dba65eb8527
Company: Cipla Europe
Type: Standard

Approval Details

Approval Id: cea82dba65eb8527
Drug Cima Aemps Name: SUGAMMADEX CIPLA 100 MG/ML SOLUCION INYECTABLE EFG
Register Number: 88319
Holder Company Name: Cipla Europe
Marketing Company Name: Cipla Europe Nv Sucursal En Espana
Authorization Date: 2022-11-25
Dosage Form: SOLUCIÓN INYECTABLE
Dose: 100 MG/ML
Route Of Administration: VÍA INTRAVENOSA
Prescription Type: Uso Hospitalario
Commercialized: Yes
Company Name: Cipla Europe

Active Ingredients

SUGAMMADEX SODIO

108,8 mg/ml

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Nov 25, 2022

Approval ID

cea82dba65eb8527

Type

Standard

Back to CIMA-AEMPS Approvals